APPLICATION OF LIQUID CHROMATOGRAPHY COUPLED WITH MASS SPECTROMETRY IN THE IMPURITY PROFILING OF DRUG SUBSTANCES AND PRODUCTS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i5.24212Keywords:
Impurities, International regulatory agencies, Hyphenated techniques, Liquid chromatography-mass spectrometryAbstract
As the drug safety and efficacy is hampered in the presence of an impurity, the international regulatory agencies laid down stringent limits for the control of impurities in the active pharmaceutical ingredient and pharmaceutical formulations. The conventional approaches lack the characterization of impurities in trace levels, due to sensitivity issues, hyphenated techniques are preferred. Among the modern hyphenated techniques, liquid chromatography-mass spectrometry (LC-MS) has high sensitivity and can analyze large number of organic compounds in a short period of time. In the present study, the impurity profiling of various drug substances and products using LC-MS about past 6 years were retrospect for its importance, instrumentations, and applications.
Downloads
References
Q3A(R2) Impurities in New drug Substances. ICH Guidelines; October 2006. Available from: http://www.ich.org/fileadmin/Public_Web_ Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2_ Guideline.pdf.
Sandor G. Identification and Determination of Impurities in Drugs. Amsterdam: Elsevier; 2000.
Saranjith S, Tarun H, Mallikarjun N, Archana S, Mahendra J, Ravi PS. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. J Pharm Biomed Anal 2012;69:148-73.
Marie L, Valerie V, Claude V, Jean-Paul B, Nicolas L, Jean-Francois G. Structural elucidation of degradation products of a benzopyridooxathiazepine under stress conditions using electron spray orbitrap mass spectrometry- study of degradation kinetic. Eur J Pharm Sci 2012;45:559-69.
Mingkun F, Quing L, Elizabeth H, Jun W. Ultra high performance liquid chromatography coupled with high resolution quantitation mass spectrometry method development and validation for determining genotoxic 2,5- dichlorobenzoyl chloride in MLN-9708 drug substance. J Pharm Biomed Anal 2014;89:233-9.
Q3C(R6) Impurities Guideline for Residual Solvents. ICH Guidelines; 2016. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Quality/Q3C/Q3C__R6___Step_4.pdf.
Q3B(R2) Impurities in New Drug Products. ICH Guidelines; 2006. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_ Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf.
Q3D Guideline for Elemental Impurities. ICH Guidelines; 2014. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_ Products/Guidelines/Quality/Q3D/Q3D_Step_4.pdf.
M7(R1). Assessment and Control of DNA Reactive (mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. ICH Guidelines; 2017. Available from: http://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/ M7_R1_Addendum_Step_4_2017_0331.pdf.
Stephen TW, Susan IW, Jay AG, Casey DB. Production and characterization of impurities in Isofluranevapourizers. Anesth Analg 1985;64:634-9.
EMA/CHMP/CVMP/QWP/450653/2006. Assessment of the Quality of Medicinal Products Containing Existing/Known Active Substances. The European Agency for the Evaluation of Medicinal Product (EMEA); 2007. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2013/11/WC500155295.pdf.
CPMP/QWP/1529/04 Control of Impurities of Pharmaceutical Substances. The European Agency for the Evaluation of Medicinal Product (EMEA); 2004. Available from: http://www.ema.europa. eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500002924.pdf.
CPMP/SWP5199/02 and EMEA/CHMP/QWP/251344/2006 Guidelines on the Limit of Genotoxic Impurities. The European Agency for the Evaluation of Medicinal Product (EMEA); 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2009/09/WC500003586.pdf.
EMEA/CHMP/SWP/4446/2000 Guideline on the Specification Limits for Residues of Metal Catalyst or Metal Reagent. The European Agency for the Evaluation of Medicinal product (EMEA); 2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500002903.pdf.
EMA/CHMP/CVMP/QWP/199250/2009 Guideline on Setting Specification for Related Impurities in Antibiotics. The European Agency for the Evaluation of Medicinal Product (EMEA); 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2012/07/WC500129997.pdf.
NDAs: Impurities in New Drug Substances. U.S Food and Drug Administration (USFDA); 2000. Available from: https://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070577.pdf.
ANDAs: Impurities in New Drug Substances. U.S Food and Drug Administration (USFDA); 2009. Available from: https://www.fda.gov/ downloads/Drugs/Guidances/UCM172002.pdf.
ANDAs: Impurities in New Drug Products. U.S Food and Drug Administration (USFDA); 2010. Available from: https://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm072861.pdf.
Elemental Impurities in Drug Products. U.S Food and Drug Administration (USFDA); 2016. Available from: https://www.fda.gov/ downloads/Drugs/Guidances/UCM509432.pdf.
Geno-toxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approach. U.S Food and Drug Administration (USFDA); 2008. Available from: https://www.fda.gov/ohrms/ dockets/98fr/fda-2008-d-0629-gdl.pdf.
Impurities in Existing Drug Substances and Products. Health Canada; 2005. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/chemical-entity-products-quality/ draft-guidance-industry-impurities-existing-drug-substances-products. html.
Guidance 18: Impurities in Drug Substances and Drug Products. Therapeutic Goods Administration (TGA); 2013. Available from: http://www.tga.gov.au/sites/default/files/pm-argpm-guidance-18.pdf.
Lameck FS, Jaffrey SM. The determination of Chlorpromazine, related impurities and degradation product in pharmaceutical dosage forms. J Pharm Biomed Anal 1989;7:271-8.
Karljikovic KR, Novovic D, Marinkovic V, Agababa D. First order UV- derivative spectrometry in the analysis of omeprazole and pantoprazole sodium salt and corresponding impurities. J Pharm Biomed Anal 2003;32:1019-27.
Sylwester M, Roman S. Quantitative determination of captopril and prednisolone in tablets by FT-Raman Spectroscopy. J Pharm Biomed Anal 2006;40:1225-30.
Jenny F, Fredrik OA, Sven PJ. NMR and Bayesian regularized neural network regression for impurity determination of 4- aminophenol. J Pharm Biomed Anal 2002;29:495-505.
Jette T, Steen H. Determination of impurities in tetracycline hydrochloride by non-aqueous capillary electrophoresis. J Chromatogr A 1996;737:291-300.
Hongyuan Y, Kyung HR. Rapid chiral separation and impurity determination of levofloxacin by ligand-exchange chromatography. Anal Chem Acta 2007;584:160-5.
James MM, Andrew CA, Donald AC. Determination of manufacturing impurities in Heroin by capillary gas chromatography with electron capture detection after derivatization with heptafluorobutyric anhydride. Anal Chem 1984;56:642-6.
Sidika E, Esra SA, Lale E, Samiye F. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets. J Pharm Biomed Anal 2003;33:1017-23.
Zhenyu W, Honggen Z, Oscar L, Brent D. Development of an orthogonal method for mometasonefuroate impurity analysis using supercritical fluid chromatography. J Chromatogr A 2011;1218:2311-9.
Krzek J, Hubicka U, Szczepanczyk J. High performance thin layer chromatography with densitometry for the determination of ciprofloxacin and impurities in drugs. J AOAC Int 2005;88:1530-6.
Swist M, Wilawmoski J, Zoba D, Kochana J, Parczewski A. Determination of synthesis route of 1-(3,4- methylenedioxyphenyl)-2- propanone (MDP-2-P) based on impurity profiles of MDMA. Forensic Sci Int 2005;149:181-92.
Novak TJ, Grinberg N, Hartman B, Marcinko S, Di Michele L, Mao B. LCMS using a hybrid quadrapole time of flight mass spectrometer for impurity identification during process chemical development of a novel integrase inhibitor. J Pharm Biomed Anal 2010;51:78-83.
Vaijanath GD, Pravin PK, Pradeep DG, Mukesh G, Bipin N, Chirag S, et al. Chracterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS. J Pharm Biomed Anal 2007;43:186-95.
Koki H, Hiroyuki Y, Koji Y, Hiroyuki N, Jun H. Novel sensitive determination method for genotoxic alkylating agent, 4-chloro-butanol, in active pharmaceutical ingredients by LC-ICP-MS employingiododerivatization. Anal Sci 2014;30:377-82.
Maria CP, Carmen GR, Alejandro C, Antonio LC, Marria LM. Identification and quantitation of cis- ketoconazole impurity by capillary zone electrophoresis-mass spectrometry. J Chromatogr A 2006;1114:170-7.
LC-MS. A Brief History. LC-GC Solutions for Separation Scientists; 2013. Available from: http://www.chromatographyonline.com/lc-ms-brief-history.
Dendeni M, Cimetiere N, Amrane A, Ben NH. Impurity profiling of trandolapril under stress testing: Structure elucidation of byproduct and development of degradation pathway. Int J Pharm 2012;438:61-70.
Ming JW, Jing X, Wen BZ, Yan W, Chang QH, Jos H, et al. Identification of the components of bitespiramycin of liquid chromatography-mass spectrometry. J Pharm Biomed Anal 2012;66:402-10.
Marvin CM. LC/MS: A practical User’s Guide. Wiley Inter Science. Hoboken: A John Wiley & Sons, Inc.; 2005.
Separation Condition 1 Fundamentals of a First Choice Mobile Phase. Shimadzu Excellence in Science. Available from: http://www. shimadzu.com/an/lcms/support/lib/lctalk/60/60lab.html.
Ali RK, Mehradad F, Farshad S, Tahmineh B, Farzad K. Determination of impurities in illicit methamphetamine sample seized in Iran. Forensic Sci Int 2012;217:204-6.
Ming-Juan W, Ya-Ping L, Yan W, Jin L, Chang-Qin H, Jos H, et al. Characterization of the components of meleumycin by liquid chromatography with photo-diode array detection and electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal 2013;84:69-76.
Szekely GY, Henriques B, Gil M, Ramos A, Alvarez C. Design of experiment as tool for LC-MS/MS method development for the trace analysis of potentially geno-toxic 4-dimethyl amino pyridine impurity in glucocorticoids. J Pharm Biomed Anal 2012;70:251-8.
Ira SL, Arthu LB, John FC, Reiko I, Joseph SB. Profiling of illicit fentanyl using UHPLC-MS/MS. Forensic Sci Int 2012;220:191-6.
Andras D, Gergo T, Jozser K, Szabolcs B. Structure elucidation of process related impurity of dapoxetine. J Pharm Biomed Anal 2014;96:272-7.
Ines G, Annabelle D, Theo H, Ivo BR, Melisande B, Christophe G, et al. Degradation pathways study of the natriuretic and β adrenoceptoranatagonisttienoxolol using liquid chromatography- electronspray ionization multistage mass spectrometry. J Pharm Biomed Anal 2014;96:56-67.
Ya-Jie Z, Jiu-Ming H, Rui-Ping Z, Yu-Cheng W, Ju-Xian W, et al. An integrated approach for detection and characterization of trace impurities in levofloxacin using liquid chromatography-tendem mass spectrometry. Rapid Commun Mass spectrom. 2014;28:1164-74.
Cuimei L, Zhendong H, Yanping B. Classification of illicit heroin by UPLC-Q-TOF analysis of acidic and neutral manufacturing impurities. Forensic Sci Int 2015;257:196-202.
Patrik P, Kim H, Stephen B. Multiple heart-cutting two dimentional liquid chromatography mass spectrometry: Towards real time determination of related impurities of biopharmaceuticals in salt based separation methods. J Chromatogr A 2016;1468:95-101.
Krishnam CR, Avadhesh KP, Gururaj S, Kaushik G, Arunima P, Sanath KG. et al. Isolation and characterization of novel degradation products of doxofylline using HPLC, FTIR, LCMS and NMR. J Pharm Biomed Anal 2017;140:1-10.
Neeraj K, Subba RD, Prasad RG, Shailendra KD, Pramod K. Synthesis, isolation, identification and characterization of new process related impurity in isoproterenol hydrochloride by HPLC, LC-ESI/MS and NMR. J Pharm Anal 2017;7:394-400.
Jin L, Dousheng Z, Chang-Qin H. Characterization of impurities in cefpodoximeproxetil using LC-MSn. Acta Pharm Sin B 2014;4:322-32.
Peixi Z, Weifeng Y, Liya H, Qiaoyuan C, Lei L, Jiajia H, et al. Characterization of a novel process related impurity in commercial bendazac lysine eye drops by LC-ESI-QTOF/MS/MS and NMR. J Pharm Biomed Anal 2015;107:437-43.
Moolchand K, Neha P, Shalu J, Prasad VB, Saranjith S. Characterization of forced degradation products oftorasemide through MS tools and explanation of unusual losses observed during mass fragmentation of drug and degradation products through density functional theory. J Pharm Biomed Anal 2017;145:209-18.
Nagdeep J, Kamaraj P, Arthanareeswari M. Gradient RP-HPLC method for the determination of potential impurities in dabigatranetexilate in bulk drug and capsule formulations. Arabian J Chem 2015; ???:???.
Custers D, Krakowska B, De Beer JO, Courselle P, Daszykowski M, Apers S, et al. Chromatographic impurity fingerprinting of genuine and counterfeit Cialis® as a means to compare the discriminating ability of PDA and MS detection. Talanta 2016;146:540-8.
Katerina G, Yannis LC, Andelija M, Vicky S, Anastasia K, Efi D, et al. Chemometrically assisted development and validation of LC-MS/MS method for the analysis of potential genotoxic impurities in meropenem active pharmaceutical ingredient. J Pharm Biomed Anal 2017;145:307-14.
Hanneke B, Arianvan A, Mattijs K, Jan D, Antione-Vender H, Peter S. Accurate quantitation of pentaerythritoltetranitrate and its degradation products using liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J Chromatogra A 2014;1338:111-6.
Kaimin X, Shanshan S, Qun G, Wei S, Yuanjiang P, Jun W. Identification of a novel low-level impurity in fungicide pyraclostrobin by high-performance liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2017;138:272-6.
Simone S, Michael L, Wolfgang L. Comprehensive impurity profiling of nutritional infusion solutions by multidimensional off-line reversed-phase liquid chromatography ×hydrophilicinteraction chromatography-ion trap mass-spectrometry and charged aerosol detection with universal calibration. J Chromatogr A 2012;1259:100-10.
Simone S, Michael L, Wolfgang L, Alexander L. Quantitative high-performance liquid chromatography–tandem mass spectrometry impurity profiling methods for the analysis of parenteral infusion solutions for amino acid supplementation containing l-alanyl-l-glutamine. J Chromatogr A 2012;1259:111-20.
Yao-Zuo Y, Mei Z, Xia-Lei F, Chang-Qin H, Shao-hong J, Ann VS, et al. Impurity profiling of etimicinsulfate by liquid chromatography ion-trap mass spectrometry. J Pharm Biomed Anal 2012;70:212-23.
Yao-Zuo Y, Mei Z, Xia-Lei F, Chang-Qin H, Shao-hong J, Ann VS, et al. Impurity profiling of micronomicinsulfate injection by liquid chromatography-ion trap mass spectrometry. J Pharm Biomed Anal 2013;75:94-104.
Yao-Zuo Y, Mei Z, Xia-Lei F, Chang-Qin H, Shao-Hong J, Ann VS, et al. Analysis of impurities in vertilmicinsulfate by liquid chromatography ion-trap mass spectrometry. J Pharm Biomed Anal 2013;80:1-8.
Yuting L, Danyi Y, Zhiyu L, Taijun H, Min S. Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques. J Pharm Biomed Anal 2016;128:253-63.
Ajay K, Subba RD, Shailendra KD, Pradeep K, Vishal S, Girish A, et al. Identification, synthesis and structural characterization of process related and degradation impurities of acrivastine and validation of HPLC method. J Pharm Biomed Anal 2017;133:15-26.
Abiramasundari A, Rahul PJ, Hitesh BJ, Jayesh AS, Dhaivath HP, Amith NP, et al. Stability-indicating assay method for determination of actarit, its process related impurities and degradation products: Insight into stability profile and degradation pathways. J Pharm Anal 2014;4:374-83.
Natasha S, Mark T, Tamsin K, Alison B, Shanlin F. Qualitative analysis of seized cocaine samples using desorption electrospray ionization- mass spectrometry (DESI-MS). Drug Test Anal 2014;7:393-400.
Elzbieta US, Anna R, Marek K, Joanna Z, Marein C, Lukasz K. Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development. Eur J Pharm Sci 2017;109:389-401.
Bo C, Zhu-Qing G, Ying L, Yang-Min Z, Ying H, Jing-Pu Z et al. Embryo and Developmental Toxicity of Cefazolin Sodium Impurities in Zebrafish; 2017. Available from: https://www.frontiersin.org/ articles/10.3389/fphar.2017.00403/full.
Jian W, Xu Y, Chunmei W, Zhijian W. Application of a trap-free two-dimensional liquid chromatography combined with ion trap/time-of-flight mass spectrometry for separation and characterization of impurities and isomers in cefpiramide. Anal Chim Acta 2017;992:42-54.
Yingping L, Bo J, Chen M, Tingting Z, Tong L. Identification of forced degradation products of tedizolid phosphate by liquid chromatography/ electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal 2017;139:221-31.
Tiaziana B, Lorenza V, Silvia B, Paulo A, Rita G. A novel automated hydrophilic interaction liquid chromatography method using diode-array detector/electrospray ionization tandem mass spectrometry for analysis of sodium risedronate and related degradation products in pharmaceuticals. J Chromatogr A 2014;1365:131-9.
Chopra S, Pendela M, Hoogmartens J, Van Schepdael A, Adams E. Impurity profiling of capreomycin using dual liquid chromatography coupled to mass spectrometry. Talanta 2012;100:113-22.
Erwin A, Larissa VS, Frederick D, Ann VS, Jos H. Characterization of impurities in josamycin using dual liquid chromatography combined with mass spectrometry. J Pharm Biomed Anal 2013;73:66-76.
Volker N, Chris B, Knut R, Christian GH. Ultrahigh-performance liquid chromatography-ultraviolet absorbance detection-high-resolution-mass spectrometry combined with automated data processing for studying the kinetics of oxidative thermal degradation of thyroxine in the solid state. J Chromatogr A 2014;1371:196-203.
Xia Z, Jin L, Chen W, Danqing S, Changqin H. Identification of impurities in macrolides by liquid chromatography–mass spectrometric detection and prediction of retention times of impurities by constructing quantitative structure–retention relationship (QSRR). J Pharm Biomed Anal 2017;145:262-72.
Yu X, DanDan W, Lan T, Jian W. Separation and characterization of allergic polymerized impurities in cephalosporins by 2D-HPSEC × LC-IT-TOF MS. J Pharm Biomed Anal 2017;145:742-50.
Sushanth BJ, Kiran CK, Rakeshwar B, Bhonsale PN. Development of RP UPLC-TOF/MS, stability indicating method foromeprazole and its related substances by applying two level factorial design; and identification and synthesis of non-pharmacopoeial impurities. J Pharm Biomed Anal 2016;118:370-9.
Saji T, Subhash CJ, Dharam V, Ashutosh A, Raghavendra DR, Sridhar I, et al. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS. J Pharm Biomed Anal 2012;63:112-9.
Thomas S, Bharti A, Maddhesia PK, Shandilya S, Agarwal A, Dharamvir, et al. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/ MS/MS. J Pharm Biomed Anal 2012;61:165-75.
Saji T, Sanjeev S, Amber B, Saroj KP, Ashutosh A, Chandra SM. Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient. J Pharm Biomed Anal 2012;57:39-51.
Xiangjun W, Hui Z, Jian-Bin Z, Chao H, Weixia L, Lushan Y, et al. Identification and characterization of four process-related impurities in retigabine. J Pharm Biomed Anal 2012;71:148-51.
Chopra S, Van Schepdael A, Hoogmartens J, Adams E. Characterization of impurities in tylosin using dual liquid chromatography combined with ion trap mass spectrometry. Talanta 2013;106:29-38.
Buchi RR, Kishore RM, Mukesh SJ, Brajesh S, Laki M. Identification, synthesis, isolation and characterization of formulation related impurity of Gabapentin. J Pharm Biomed Anal 2016;129:509-13.
Robert JD, Elaine S, Wenzhou L, Szilan F. Evidence for an imidazoline by-product from glycans using tandem mass spectrometry. J Chromatogr A 2017;1501:61-7.
Ruggenthaler M, Grass J, Schuh W, Huber CG, Reischl RJ. Impurity profiling of liothyronine sodium by means of reversed phase HPLC, high resolution mass spectrometry, on-line H/D exchange and UV/Vis absorption. J Pharm Biomed Anal 2017;143:147-58.
Musty S, Ravichandra BR. Determination and characterization of process related impurities in pazopanib hydrochloride drug substance. Int J Pharm Pharm Sci 2016;8:294-9.
Mayuri P, Krishna D, Krishnapriya M. Isocratic LC-UV, LC-MS and MS/MS studies on fenoxazoline and its degradation products. Int J Pharm Pharm Sci 2015;7:50-7.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
